Skip to main content

Advertisement

SpringerLink
Log in

Surveillance MR Imaging is Superior to Serum Tumor Markers for Detecting Early Tumor Recurrence in Patients with Appendiceal Cancer Treated with Surgical Cytoreduction and HIPEC

  • Regional Cancer Therapies
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The purpose of this study was to determine if MRI surveillance is better than serum tumor makers in detecting early recurrence in patients with mucinous appendiceal neoplasm.

Materials and Methods

A total of 50 patients with appendiceal neoplasm (DPAM 11, PMCA 39) underwent abdominal and pelvic MRI prior to surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients then entered follow-up surveillance with serial MRI every 6 months and serial laboratory studies including CA 125, CEA, and CA19-9. Written reports for surveillance MRI exams were reviewed for tumor recurrence and compared with results of serial laboratory tests. Proof of tumor recurrence was by a consensus of surgery and histopathology, as well as clinical and imaging findings on serial examinations.

Results

During surveillance tumor recurrence was documented in 30 patients (60 %) with median time to recurrence of 13 months (range 3–56 months). MRI detected recurrent tumor in 28 patients, including 11 patients with normal laboratory values (sensitivity 0.93, specificity 0.95, accuracy 0.94, PPV 0.97, and NPV 0.90). Serial laboratory values showed tumor recurrence in 14 patients (sensitivity 0.48, specificity 1.00, accuracy 0.69, PPV 1.0, and NPV 0.57). Median survival was 50 months for 11 patients with earlier MRI detection of recurrence vs 33 months for the other 19 patients with recurrence.

Conclusions

Following cytoreductive surgery and HIPEC MRI detects tumor recurrence earlier and with greater accuracy than serial tumor markers alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14:2289–99.

    Article  PubMed  Google Scholar 

  2. Bijelic L, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol. 2008;15;98:295–9.

    Google Scholar 

  3. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104–9.

    Article  PubMed  Google Scholar 

  4. Sugarbaker PH. New standard of care for epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.

    Article  PubMed  Google Scholar 

  5. Baratti D, Dusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–34.

    Article  PubMed  Google Scholar 

  6. Vaira M, Cioppa T, De Marco G, Bing C, D’Amico S, D’Alessandro M, et al. Management of pseudomyxoma peritonei by cytoreduction + HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo. 2009;4:639–44.

    Google Scholar 

  7. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16:1903–11.

    Article  PubMed  Google Scholar 

  8. Vaira M, Cioppa T, DE Marco G, Bing C, D’Amico S, D’Alessandro M, Fiorentini G, DE Simone M. Management of pseudomyxoma peritonei by cytoreduction + HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo. 2009;23:639–44.

    PubMed  Google Scholar 

  9. Winder T, Lenz HJ. Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. The Oncologist. 2010;8:836–44.

    Article  Google Scholar 

  10. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576–81.

    Article  PubMed  Google Scholar 

  11. Glenhen O, Gilly FN. Quantitative preoperative indicators of peritoneal surface malignancies: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649–71.

    Article  Google Scholar 

  12. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:3. http://www.issoonline.com/content/2/1/3.

  13. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–32.

    Article  PubMed  CAS  Google Scholar 

  14. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–80.

    PubMed  CAS  Google Scholar 

  15. Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.

    Google Scholar 

  16. Jacquet P, Jelinek JS, Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181:530–8.

    PubMed  CAS  Google Scholar 

  17. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002;223:495–500.

    Article  PubMed  Google Scholar 

  18. Koh JL, Tan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.

    Article  PubMed  Google Scholar 

  19. Low RN, Barone RM, Gurney JM. Mucinous appendiceal neoplasms: preoperative MR staging and classification compared with surgical and histopathologic findings. Am J Roentgenol. 2008;190:656–65.

    Article  Google Scholar 

  20. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings—a feasibility study. Am J Roentgenol. 2009;193:461–70.

    Article  Google Scholar 

  21. Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MR imaging can accurately predict the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann. Surg Oncol. 2012;19:1394–401.

    Article  PubMed  Google Scholar 

  22. Low RN, Duggan B, Barone RM, Saleh F, Song SYT. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology. 2005;235:918–26.

    Article  PubMed  Google Scholar 

  23. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12:703–27.

    Article  Google Scholar 

  24. Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis. 2005;7,382–6.

    Article  PubMed  CAS  Google Scholar 

  25. Verwaal VJ, Boot H, Aleman BMP, Van Tinteren H, Zoetmulder FAN. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.

    Article  PubMed  Google Scholar 

  26. van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2002;9:961–7.

    Article  PubMed  Google Scholar 

  27. Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2010;36:772–6.

    Article  PubMed  CAS  Google Scholar 

  28. Sugarbaker PH, Jacquet P. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Chapter 23. In: Jacquet P, Sugarbaker PH, editors, Peritoneal Carcinomatosis: Principles of Management. New York: Springer; 1996.

  29. Esquivel J, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: Analysis of prognostic factors in 98 patients. Ann Surg. 2001;234:198–205.

    Article  PubMed  CAS  Google Scholar 

  30. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–70.

    Article  PubMed  CAS  Google Scholar 

  31. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic xrays: estimates for the UK and 14 other countries. Lancet. 2004;363:345–51.

    Google Scholar 

  32. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. Am J Roentgenol. 2001;176:289–96.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sharp and Children’s MRI Center, San Diego, California

    Russell N. Low MD

  2. Department of Surgical Oncology, Sharp Memorial Hospital, San Diego, California

    Robert M. Barone MD

  3. University of California at San Diego, La Jolla, California

    Melissa J. Lee MS

Authors
  1. Russell N. Low MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Barone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melissa J. Lee MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell N. Low MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Low, R.N., Barone, R.M. & Lee, M.J. Surveillance MR Imaging is Superior to Serum Tumor Markers for Detecting Early Tumor Recurrence in Patients with Appendiceal Cancer Treated with Surgical Cytoreduction and HIPEC. Ann Surg Oncol 20, 1074–1081 (2013). https://doi.org/10.1245/s10434-012-2788-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2788-2

Keywords

Search

Navigation